See All Slides - tctmd.com

Slides

Presentation TCT 2012

Blue-Toe Syndrome: Does Thrombolysis Have a Place?

Presenter: Thomas McNamara

October 23, 2012

Presentation TCT 2012

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Ken Kozuma

October 25, 2012

Presentation TCT 2012

Cerebral Embolic Protection during TAVR: Metrics for Evaluating Safety and Efficacy

Presenter: Martyn Thomas

October 25, 2012

Presentation TCT 2012

Plasmonic Photothermal Therapy of Atherosclerotic Lesions with Silica-Gold Nanoparticles

Presenter: Alexander Kharlamov

October 22, 2012

Presentation TCT 2012

If You Want the Truth, Randomize!

Presenter: Robert Harrington

October 24, 2012

Presentation TCT 2012

Case 1: Patient with Stable Class 1 Angina Treated with Aspirin and Statin and a Mid LAD 70% Stenosis(2)

Presenter: Megan Coylewright

October 26, 2012

Presentation TCT 2012

Circulatory Support for Cardiogenic Shock

Presenter: E. Magnus Ohman

October 23, 2012

Presentation TCT 2012

Treatment of Acute Decompensated HF

Presenter: Dennis McNamara

October 23, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Presentation TCT 2012

Is Intraaortic Balloon Counterpulsation Really Useful in Cardiogenic Shock? Results of the IABP-SHOCK II Trial

Presenter: Holger Thiele

October 25, 2012

Advertisement

Slides

Blue-Toe Syndrome: Does Thrombolysis Have a Place?

RESET 2-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Cerebral Embolic Protection during TAVR: Metrics for Evaluating Safety and Efficacy

Plasmonic Photothermal Therapy of Atherosclerotic Lesions with Silica-Gold Nanoparticles

If You Want the Truth, Randomize!

Case 1: Patient with Stable Class 1 Angina Treated with Aspirin and Statin and a Mid LAD 70% Stenosis(2)

Circulatory Support for Cardiogenic Shock

Treatment of Acute Decompensated HF

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Is Intraaortic Balloon Counterpulsation Really Useful in Cardiogenic Shock? Results of the IABP-SHOCK II Trial

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content